急性細菌性皮膚和皮膚結構感染疾病市場規模（按感染類型、藥物類型、給藥途徑、分銷管道、區域覆蓋範圍和預測）

急性細菌性皮膚和皮膚結構感染疾病（ABSSSI）的市場規模和預測

急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 市場規模在 2024 年價值 114.9 億美元，預計到 2032 年將達到 239.4 億美元，2026 年至 2032 年的複合年成長率為 9.6%。

急性細菌性皮膚及皮膚結構感染疾病(ABSSSI) 是指皮膚及皮下軟組織的嚴重細菌感染疾病，必須立即使用抗生素治療。這類感染包括蜂窩組織炎組織炎、丹毒、嚴重皮膚膿瘍和傷口感染。

腹腔鏡皮膚感染 (ABSSSI) 通常由革蘭氏陽性菌引起，尤其是葡萄球菌，例如抗藥性金黃色葡萄球菌(MRSA) 和鏈球菌。如果沒有有效治療，這些感染疾病可能導致嚴重的併發症，症狀包括患處發紅、腫脹、不適和發熱。

全球急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 市場動態

影響急性細菌性皮膚和皮膚結構感染疾病市場的關鍵市場動態是：

關鍵市場促進因素

皮膚和軟組織感染疾病盛行率不斷上升：皮膚和軟組織感染疾病（尤其是非小細胞肺癌感染，ABSSSI）的盛行率不斷上升，是推動該市場發展的主要動力。根據美國疾病管制與預防中心 (CDC) 的數據，2015美國美國約有 1,420 萬人次因皮膚和軟組織感染疾病就診。如此高的盛行率凸顯了改進 ABSSSI治療方法的迫切需求。

抗生素抗藥性日益加劇：人們對抗生素抗藥性細菌日益成長的擔憂，正在推動針對ABSSSIs的新治療方法的開發。根據世界衛生組織 (WHO) 的數據，抗生素抗藥性病菌感染在2019年造成超過120萬人死亡。這種令人擔憂的狀況正在推動對ABSSSIs新藥和新治療方案的需求。

醫療保健支出不斷成長：全球醫療保健支出的不斷成長正在推動ABSSSIs市場的發展。根據世界銀行的數據，全球醫療保健支出佔GDP的比重從2000年的8.5%上升到2019年的9.8%。醫療保健投資的不斷增加正在改善ABSSSIs等疾病的治療方法可近性，尤其是在富裕國家。

主要挑戰

開發成本高：研發新的ABSSSI藥物和治療方法需要大量的研發投入。該技術成本高昂，阻礙了製藥公司在該領域的投資，限制了產品的可用性和創新。

治療方案有限：儘管對有效ABSSSI治療的需求日益成長，但核准的治療藥物卻寥寥無幾。缺乏便捷的治療方案限制了患者的選擇，阻礙了市場的快速成長。

抗生素抗藥性：抗生素抗藥性細菌日益普遍，導致急性腹腔感染 (ABSSSI) 難以有效治療。這降低了現有抗生素的有效性，同時也增加了對創新治療方案的需求，而這些方案的開發既困難又耗時。

主要趨勢

提高認知和盛行率：由於皮膚和軟組織感染疾病的增加，特別是在免疫力缺乏的患者和患有慢性疾病的患者中，人們對 ABSSSI 的盛行率和發病率不斷上升的認知不斷提高，從而推動了市場的發展。

治療方法的進步：診斷和治療技術的進步正在改變ABSSSI市場。先進的影像技術和快速診斷檢測有助於早期發現，從而及時介入並改善患者預後。

製藥公司越來越注重研發：製藥公司越來越注重研發，包括開發針對抗生素抗藥性菌株的新型藥物和治療方法，以滿足以前未滿足的醫療需求。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

4. 急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 市場（依感染類型）

• 醫院獲得性 ABSSSI
• 社區型 ABSSSI

5. 急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 市場（依藥物類型）

• 口服抗生素
• 局部抗生素

6. 急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 市場（依給藥途徑）

• 口服
• 腸外給藥
• 局部的

7. 急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 市場（依分銷管道）

• 醫院藥房
• 零售藥局
• 網路藥局
• 其他

第8章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第9章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第10章 競爭格局

• 主要企業
• 市場佔有率分析

第11章 公司簡介

• Pfizer Inc.
• Merck & Co., Inc.
• AstraZeneca plc
• F. Hoffmann-La Roche Ltd
• Bayer AG
• GlaxoSmithKline plc
• Sanofi SA
• Paratek Pharmaceuticals, Inc.
• Melinta Therapeutics, Inc.

第12章 市場展望市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第13章 附錄

• 簡稱列表
• 來源和參考文獻

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Size and Forecast

Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market size was valued at USD 11.49 Billion in 2024 and is projected to reach USD 23.94 Billion by 2032, growing at a CAGR of 9.6% from 2026 to 2032.

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are severe bacterial infections of the skin and underlying soft tissues that must be treated immediately with antibiotics. They include cellulitis, erysipelas, severe cutaneous abscesses, and wound infections.

ABSSSIs are typically caused by Gram-positive bacteria, particularly Staphylococcus and Streptococcus species, such as methicillin-resistant Staphylococcus aureus (MRSA). If not treated effectively, these infections can cause severe morbidity, with symptoms including redness, swelling, discomfort, and warmth at the affected site.

Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Dynamics

The key market dynamics that are shaping the acute bacterial skin and skin structure infection market include:

Key Market Drivers

Increasing Prevalence of Skin and Soft Tissue Infections: The increased frequency of skin and soft tissue infections, especially ABSSSIs, is a major driver of this market. According to the US Centers for Disease Control and Prevention (CDC), there were approximately 14.2 million outpatient consultations for skin and soft tissue infections in the United States in 2015. This high prevalence highlights the urgent need for improved therapies for ABSSSI.

Rising Antibiotic Resistance: The growing concern about antibiotic-resistant bacteria is pushing the development of new treatments for ABSSSI. According to the World Health Organization (WHO), antibiotic-resistant bacterial infections killed more than 1.2 million people in 2019. This concerning development is driving the need for new medicines and treatment options for ABSSSIs.

Increasing Healthcare Expenditure: The global increase in healthcare spending is boosting the ABSSSI market. According to the World Bank, worldwide health expenditure as a proportion of GDP increased from 8.5% in 2000 to 9.8% in 2019. This increased healthcare investment is improving access to therapies for illnesses such as ABSSSIs, especially in wealthy countries.

Key Challenges:

High Development Costs: Significant research and development investments are required to create novel ABSSSI medicines and therapies. The high costs of this technique deter pharmaceutical companies from investing in this field, restricting product availability and innovation.

Limited Treatment Options: Despite the increasing demand for effective ABSSSI treatments, there are just a few authorized medications available. The scarcity of accessible treatment choices limits patient options and inhibits the market from growing as quickly as it can.

Antibiotic Resistance: Antibiotic-resistant bacterial strains are becoming increasingly common, making it difficult to treat ABSSSIs effectively. This diminishes the efficacy of current antibiotics while increasing the demand for innovative therapeutic options, which are difficult and time-consuming to develop.

Key Trends:

Growing Awareness and Prevalence: The market is being driven by increased awareness of the prevalence of ABSSSI, as well as rising incidence rates. This trend is caused by an increase in skin and soft tissue infections, particularly among immunocompromised people and those suffering from chronic conditions.

Advancements in Treatment Options: Technological advances in diagnoses and treatment techniques are transforming the ABSSSIs market. Advanced imaging techniques and speedy diagnostic tests promote early detection, resulting in timely interventions and better patient outcomes.

R&D Initiatives by Pharmaceutical Companies: Pharmaceutical companies are increasingly focusing on R&D. This includes the creation of novel medications and therapy targeted to antibiotic-resistant strains, thereby meeting previously unmet medical requirements.

Global Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market Regional Analysis

Here is a more detailed regional analysis of the acute bacterial skin and skin structure infection market:

North America:

According to Verified Market Research, North America is estimated to dominate the acute bacterial skin and skin structure infection market over the forecast period. Skin and soft tissue infections, including ABSSSIs, are common in North America, especially in the United States. In 2014, the United States Centers for Disease Control and Prevention (CDC) reported roughly 3.4 million emergency department visits for skin and soft tissue infections. This high prevalence increases the demand for ABSSSI therapies in the region.

North America has a well-developed healthcare system and high healthcare spending, which allows for improved detection and treatment of ABSSSIs. According to the Centers for Medicare and Medicaid Services, healthcare spending in the United States increased by 4.6% in 2019, to USD 3.8 Trillion, or $11,582 per person. This level of spending encourages the use of newer, more effective therapies for ABSSSI.

Furthermore, MRSA is a common cause of ABSSSIs, and its presence in North America serves as a substantial market driver. The CDC estimates that approximately 2% of the population has MRSA. In 2017, there were around 323,700 cases of MRSA in hospitalized patients in the United States. This high occurrence of antibiotic-resistant illnesses necessitates the development of sophisticated ABSSSI treatments in the region.

Europe:

Europe region is estimated to exhibit substantial growth during the forecast period. Europe has a high incidence of skin and soft tissue infections, particularly ABSSSIs. According to the European Centre for Disease Prevention and Control (ECDC), surgical site infections, a kind of ABSSSI, were reported in 3.2% of surgical procedures in Europe in 2019. This high prevalence increases the demand for effective therapies in the region.

The increasing prevalence of antibiotic-resistant bacteria in Europe is driving the discovery and implementation of innovative treatments for ABSSSIs. According to the ECDC, over 33,000 persons in the EU/EEA died as a result of antibiotic-resistant bacterial illnesses in 2019. Methicillin-resistant Staphylococcus aureus (MRSA), a prevalent cause of ABSSSIs, is still a major public health concern, with MRSA accounting for more than 25% of Staphylococcus aureus isolates in seven of the 29 countries studied.

Furthermore, the aging of Europe's population, as well as the rise of chronic diseases, help to drive the ABSSSI market forward. According to Eurostat, the proportion of people aged 65 and up in the EU is expected to rise from 20.3% in 2019 to 29.4% in 2050. ABSSSIs are more likely to affect older persons and those with chronic diseases such as diabetes. According to the International Diabetes Federation, 59 million adults in Europe had diabetes in 2019, and this figure is anticipated to climb to 68 million by 2045, thereby increasing the incidence of ABSSSIs.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The Asia Pacific region has a large population, which naturally results in a higher incidence of ABSSSI cases. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's population is predicted to increase from 4.3 billion in 2020 to 4.7 billion in 2050. This population increase translates to a larger patient pool for ABSSSIs, which drives market growth.

Diabetes poses a considerable risk for skin infections, especially ABSSSIs. According to the International Diabetes Federation (IDF), the number of adults living with diabetes in the Western Pacific region (which includes much of Asia) is anticipated to rise from 163 million in 2019 to 212 million by 2045. The rising prevalence of diabetes is anticipated to contribute to an increased incidence of ABSSSIs in the region.

Furthermore, the Asia Pacific region is rapidly improving its healthcare infrastructure and access. According to the World Health Organization (WHO), health expenditure as a proportion of GDP in Southeast Asia rose from 3.5% in 2000 to 4.4% in 2017. Improved healthcare spending and infrastructure development are improving diagnostic and treatment capabilities for illnesses such as ABSSSIs, resulting in market growth.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market: Segmentation Analysis

The Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market is segmented based on Infection Type, Drug Type, Route of Administration, Distribution Channel, and Geography.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Infection Type

• Hospital-acquired ABSSSI
• Community-acquired ABSSSI

Based on Infection Type, the market is segmented into Hospital-acquired ABSSSI and Community-acquired ABSSSI. The hospital-acquired ABSSSI segment is estimated to dominate the acute bacterial skin and skin structure infection market due to the high incidence of hospital-acquired ABSSSI cases caused by variables such as impaired skin integrity, the presence of multi-drug resistance organisms in healthcare settings, and immunosuppressed patients' susceptibility to severe infections.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Drug Type

• Oral & Parental Antibiotics
• Topical Antibiotics

Based on Drug Type, the market is segmented into Oral & Parental Antibiotics and Parental Antibiotics. The oral & parental antibiotics segment is estimated to dominate the acute bacterial skin and skin structure infection market during the forecast period owing to their great efficiency against a wide spectrum of bacterial illnesses and convenience of administration via the oral route. Parenteral antibiotics are especially important in severe cases because they provide increased bioavailability and tissue penetration, which is critical for treating illnesses such as bacteremia and sepsis.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Route of Administration

• Oral
• Parental
• Topical

Based on the Route of Administration, the market is segmented into Oral, Parental, and Topical. The parental segment is estimated to dominate the acute bacterial skin and skin structure infection market because parenteral antibiotics can quickly enter the bloodstream and successfully battle severe ABSSSI cases. The parenteral method is preferable for its quick drug administration and tailored treatment approach, particularly in urgent ABSSSI cases requiring prompt action.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Based on the Distribution Channel, the market is segmented into Hospital, Retail, Online, and Others. The hospital pharmacies segment is estimated to dominate the acute bacterial skin and skin structure infection market. Hospital pharmacies play an important role in ABSSSI therapy because they provide prompt access to essential medicines and work closely with healthcare teams to develop antibiotic regimens. Furthermore, hospital pharmacies help patients make a smooth transition to outpatient care by giving drugs upon release, assuring thorough and efficient ABSSSI therapy.

Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the acute bacterial skin and skin structure infection market is classified into North America, Europe, Asia Pacific, and the Rest of the World. According to the VMR analyst, North America is estimated to dominate during the forecasted period due to leading pharmaceutical companies' substantial research operations, a focus on creating anti-MRSA medications, and the introduction of new products. North America's market revenue is predicted to remain dominant due to the region's robust healthcare infrastructure and widespread awareness of ABSSSIs.

Key Players

• The "Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer, Inc., Merck & Co., Inc., AstraZeneca plc, Hoffmann-La Roche Ltd, Bayer AG, GlaxoSmithKline plc, Sanofi S.A., Paratek Pharmaceuticals, Inc., and Melinta Therapeutics, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Acute Bacterial Skin and Skin Structure Infection Market Recent Developments
• In July 2021, Melinta Therapeutics, a pharmaceutical firm, released KIMYRSA, as a lipoglycopeptide antibiotic efficacious for treating acute bacterial skin and skin structure infections (ABSSSI) in a single 1200mg injectable dose.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Type of Infection

• Hospital-acquired ABSSSI
• Community-acquired ABSSSI

5. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Drug Type

• Oral & Parenteral Antibiotics
• Topical Antibiotics

6. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Route of Administration

• Oral
• Parenteral
• Topical

7. Acute Bacterial Skin And Skin Structure Infection (ABSSSI) Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

8. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

9. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

10. Competitive Landscape

• Key Players
• Market Share Analysis

11. Company Profiles

• Pfizer Inc.
• Merck & Co., Inc.
• AstraZeneca plc
• F. Hoffmann-La Roche Ltd
• Bayer AG
• GlaxoSmithKline plc
• Sanofi S.A.
• Paratek Pharmaceuticals, Inc.
• Melinta Therapeutics, Inc.

12. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

13. Appendix

• List of Abbreviations
• Sources and References